Cysteine-depleted muteins of biologically active proteins
CA 1340861 C · Owner: Novartis Vaccines And Diagnostics, Inc. · Inventors: Lin, S. Leo; Yu Lu, Shi-Da; Mark, F. David
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Muteins of biologically active proteins such as IFN-.beta. and IL-2 in which, cysteine residues that are not essential to biological activity have been replaced with other amino acids, or in the case of IFN-.beta. deleted or replaced, with other amino acids, to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bridge formation. These muteins are made via bacterial expression of mutant genes that encode the muteins that have been synthesized from the genes for the parent proteins by oligonucleotide-directed mutagenesis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted December 28, 1999. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended December 28, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.